Chief Scientific Officer
Guy joined Isogenica in January 2016. He brings in over a decade of experience in antibody fragment discovery and early development, as well as antibody discovery technology development.
At Ablynx, he conceived of many of its internal drug development programs, leading many through the early R&D stages as well. He was also responsible for a number of lead generation technology development programs to enable lead generation to challenging targets, or enable novel applications.
Apart from this, he introduced prospective partner pharma companies to domain antibody technology and served in joint research committees in projects stages ranging from drafting and negotiating work plans through to lead generation up to in vivo PoC.
Prior to joining Ablynx, Guy did research in the pathogenesis and immunotherapy of autoimmune and inflammatory disorders, ranging from preclinical in vitro/in vivo target discovery and validation work up to cell-based immunotherapy clinical trials in Multiple Sclerosis patients.
Guy holds a Master’s degree in Biotechnology from the University of Ghent and a PhD in Medicine from the University of Hasselt. He completed postdoctoral training at Stanford University Medical School.